RSS Feed
March 5th, 2016 
Awake Goy 
Susanne Posel ,Chief Editor Occupy Corporatism | Co-Founder, HEALTH MAX
Personalized medicine is the future of healthcare and a recent breakthrough in the burgeoning industry is making waves.
At the University College London (UCL), scientists have provided more evidence that immunotherapies are not only cutting edge technology, but will advance cancer treatments in just a matter of a few years.
Merck, Bristol-Myers Squibb and others are investing in medications such as Keytruda and Opdivo because of their precision medicine properties.
In fact, former US President Jimmy Carter was treated using immunotherapies when he was cleared of cancer in 2015.
Immunotherapies have helped the medical insurance industry add to their mounting profit margins.
In 2014, Last year the National Conference of State Legislators (NCSL) explained that the value-based insurance design (VBID) is “health benefits [that] can be designed” for the patient.
Focusing on preventive medicine, wellness visits to the physician and pharmaceutical treatments used to manage or reduce illnesses and disease is sold as a good way for customers to save money and possibly eliminate “future expensive medical procedures”.
One way to ensure the VBID works is the implementation of “high cost-sharing, for health choices that may be unnecessary or repetitive” based on health data on the customer.
Just last year, UnitedHealth Group (UHG) announced their impressive up-swing in profits will continue to rise in 2015 thanks to the Affordable Care Act (ACA).
With value-based care and precision medicine, contracts were pushed onto doctors and hospitals, worth an estimated $2 billion.
Also in 2015, President Obama announced the Precision Medicine Initiative (PMI) in order to “usher in a new era of medicine that will harness data to support and advance research, technology and policies and to empower health care providers and patients … that builds on the work that was done in mapping out the human genome.”
Prior to this announcement, the Obama administration revealed PMI requires the creation of a “1 million-plus patient repository of genetic information spanning many diseases, giving researchers valuable insights to design the next generation of treatments for patients.”
Speaking at a summit on health and science , the president spoke about “spurring on a whole new set of understandings about how diseases operate, about how the human body, how cells operate, how areas like cancer show how each cancer may be unique, even if it’s in the same organ.”
PMI is described as “tailoring medicine to [individual], unique biological needs” and the matching of a diagnosis and “treatment strategy to each individual’s unique molecular makeup.”
At the time of the PMI launch, the president asked for $215 million to pay for a way to “revolutionize the way we approach health in this country and, ultimately, around the world.”
While medicine has historically developed out of the need for the “average” person, the “result of this one-size-fits-all-approach, treatments can be very successful for some patients but not for others.”
Related Posts
Source Article from http://feedproxy.google.com/~r/OccupyCorporatism/~3/NNq8oM8h84A/
Posted in 
